Groupe Hospitalier De La Region De Mulhouse Et Sud Alsace

The department is conducting research on Mycobacterium xenopi pulmonary infection, aiming to improve treatment outcomes through innovative inhaled antibiotic approaches.

• Evaluation of an inhaled liposomal amikacin formulation
• Assessment of 3‑month sputum conversion rates
• Comparison with standard antibiotic regimens
• Monitoring of safety and tolerability in respiratory patients

These studies are carried out at Groupe Hospitalier De La Region De Mulhouse Et Sud Alsace, contributing to better management of difficult‑to‑treat bacterial lung infections.

Researchers are exploring new therapeutic combinations for myelofibrosis, focusing on disease control in patients who have not received prior treatment.

• Combination of a nuclear export inhibitor with a JAK pathway blocker
• Impact on symptom burden and spleen size
• Evaluation of treatment‑naïve patient response
• Long‑term safety monitoring

The work at this Mulhouse hospital aims to expand options for patients with advanced hematologic disorders.

The pneumology unit is investigating an oral agent for Diabetic Peripheral Neuropathic Pain, with the goal of reducing pain intensity and improving daily function.

• Measurement of pain score changes over time
• Patient‑reported outcome assessments
• Safety and tolerability in a diabetic population
• Comparison against placebo treatment

This research provides hope for individuals living with chronic neuropathic pain associated with diabetes.

A study targeting Systemic Lupus Erythematosus is evaluating a novel oral therapy designed to modulate immune activity and lower disease activity scores.

• Assessment of clinical disease activity indices
• Evaluation of immune pathway modulation
• Impact on quality of life measures
• Safety profile in adult participants

Conducted at the Mulhouse research site, this work seeks to broaden therapeutic choices for patients with autoimmune disease.